Nalaganje...
Bioavailability of everolimus administered as a single 5 mg tablet versus five 1 mg tablets: a randomized, open-label, two-way crossover study of healthy volunteers
BACKGROUND: The mammalian target of rapamycin (mTOR) inhibitor everolimus has a well-established pharmacokinetics profile. We conducted a randomized, single-center, open-label, two-sequence, two-period crossover study of healthy volunteers to assess the relative bioavailability of everolimus adminis...
Shranjeno v:
| izdano v: | Clin Pharmacol |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2015
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4310326/ https://ncbi.nlm.nih.gov/pubmed/25653564 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CPAA.S73472 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|